top of page

2024

A20 HAPLOINSUFFICIENCY DISTURBS IMMUNE HOMEOSTASIS AND DRIVES THE TRANSFORMATION OF LYMPHOCYTES WITH PERMISSIVE ANTIGEN RECEPTORS.

Schultheiß C, Paschold L, Mohebiany AN, Escher M, Kattimani YM, Müller M, Schmidt-Barbo P, Mensa-Vilaró A, Aróstegui JI, Boursier G, de Moreuil C, Hautala T, Willscher E, Jonas H, Chinchuluun N, Grosser B, Märkl B, Klapper W, Oommen PT, Gössling K, Hoffmann K, Tiegs G, Czernilofsky F, Dietrich S, Freeman A, Schwartz DM, Waisman A, Aksentijevich I, Binder B.


B CELLS EXPRESSING MUTATED IGHV1-69-ENCODED ANTIGEN RECEPTORS RELATED TO VIRUS-NEUTRALIZATION SHOW LYMPHOMA-LIKE TRANSCRIPTOMES IN PATIENTS WITH CHRONIC HCV INFECTION.

Schultheiß C, Willscher E, Paschold L, Ackermann C, Escher M, Scholz R, Knapp M, Lützkendorf J, Müller LP, Schulze-zur-Wiesch J, Binder M.

HOUSEHOLD TRANSMISSION OF OMICRON VARIANT OF SARS-COV-2 UNDER CONDITIONS OF HYBRID IMMUNITY-A PROSPECTIVE STUDY IN GERMANY.

Klee B, Diexer S, Xu C, Gottschick C, Hartmann C, Meyer-Schlinkmann KM, Kuhlmann A, Rosendahl J, Binder M, Gekle M, Girndt M, Höll JI, Moor I, Sedding D, Moritz S, Frese T, Mikolajczyk R.

TRIFLURIDINE/TIPIRACIL BASED CHEMORADIATION IN LOCALLY ADVANCED RECTAL CANCER: THE PHASE I/II TARC TRIAL.

Thiele B, Stein A, Schultheiß C, Paschold L, Jonas H, Goekkurt E, Rüssel J, Schuch G, Wierecky J, Sinn M, Tintelnot J, Petersen C, Rothkamm K, Vettorazzi E, Binder M.

DETECTION OF DISEASE-SPECIFIC SIGNATURES IN B CELL REPERTOIRES OF LYMPHOMAS USING MACHINE LEARNING.

Schmidt-Barbo P, Kalweit G, Naouar M, Paschold L, Willscher E, Schultheiß C, Märkl B, Dirnhofer S, Tzankov A, Binder M, Kalweit M.

THE CONTRIBUTION OF SARS-COV-2 TO THE BURDEN OF ACUTE RESPIRATORY INFECTIONS IN WINTER SEASON 2022/2023: RESULTS FROM THE DIGIHERO STUDY.

Glaser N, Diexer S, Klee B, Purschke O, Binder M, Frese T, Girndt M, Höll J, Moor I, Rosendahl J, Gekle M, Sedding D, Mikolajczyk R, Gottschick C.

NKP44/HLA-DP-DEPENDENT REGULATION OF CD8 EFFECTOR T CELLS BY NK CELLS.

Padoan B, Casar C, Krause J, Schultheiss C, Baumdick ME, Niehrs A, Zecher BF, Pujantell M, Yuki Y, Martin M, Remmerswaal EBM, Dekker T, van der Bom-Baylon ND, Noble JA, Carrington M, Bemelman FJ, van Lier RAW, Binder M, Gagliani N, Bunders MJ, Altfeld M.

INSIGHTS INTO EARLY RECOVERY FROM LONG COVID-RESULTS FROM THE GERMAN DIGIHERO COHORT.

Diexer S, Klee B, Gottschick C, Broda A, Purschke O, Binder M, Gekle M, Girndt M, Hoell JI, Moor I, Sedding D, Rosendahl J, Mikolajczyk R.

TOLERABILITY AND EFFICACY OF THE CANCER VACCINE UV1 IN PATIENTS WITH RECURRENT OR METASTATIC PD-L1 POSITIVE HEAD AND NECK SQUAMOUS CELL CARCINOMA PLANNED FOR FIRST-LINE TREATMENT WITH PEMBROLIZUMAB - THE RANDOMIZED PHASE 2 FOCUS TRIAL

Brandt A, Schultheiss C, Klinghammer K, Schafhausen P, Busch CJ, Blaurock M, Hinke A, Tometten M, Dietz A, Müller-Richter U, Hahn D, Alt J, Stein A, Binder M.

SARS-COV-2 VACCINATION MAY MITIGATE DYSREGULATION OF IL-1/IL-18 AND GASTROINTESTINAL SYMPTOMS OF THE POST-COVID-19 CONDITION

Fischer C, Willscher E, Paschold L, Gottschick C, Klee B, Diexer S, Bosurgi L, Dutzmann J, Sedding D, Frese T, Girndt M, Hoell JI, Gekle M, Addo MM, Schulze Zur Wiesch J, Mikolajczyk R, Binder M, Schultheiß C.

MUTATION-SPECIFIC CAR T CELLS AS PRECISION THERAPY FOR IGLV3-21R110 EXPRESSING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA

Märkl F, Schultheiß C, Ali M, Chen SS, Zintchenko M, Egli L, Mietz J, Chijioke O, Paschold L, Spajic S, Holtermann A, Dörr J, Stock S, Zingg A, Läubli H, Piseddu I, Anz D, Minden MD, Zhang T, Nerreter T, Hudecek M, Minguet S, Chiorazzi N, Kobold S, Binder M.

SARS-COV-2-ASSOCIATED T-CELL INFILTRATION IN THE CENTRAL NERVOUS SYSTEM

Mohme M, Schultheiß C, Piffko A, Fitzek A, Paschold L, Thiele B, Püschel K, Glatzel M, Westphal M, Lamszus K, Matschke J, Binder M.

RAMUCIRUMAB, AVELUMAB, AND PACLITAXEL AS SECOND-LINE TREATMENT IN ESOPHAGOGASTRIC ADENOCARCINOMA: THE PHASE 2 RAP (AIO-STO-0218) NONRANDOMIZED CONTROLLED TRIAL

Thuss-Patience P, Högner A, Goekkurt E, Stahl M, Kretzschmar A, Götze T, Stocker G, Reichardt P, Kullmann F, Pink D, Bartels P, Jarosch A, Hinke A, Schultheiß C, Paschold L, Stein A, Binder M.

2023

REGIONAL DIFFERENCES IN UPTAKE OF VACCINATION AGAINST COVID-19 AND INFLUENZA IN GERMANY: RESULTS FROM THE DIGIHERO COHORT

Klee B, Diexer S, Sarajan MH, Glaser N, Binder M, Frese T, Girndt M, Sedding D, Hoell JI, Moor I, Gekle M, Mikolajczyk R, Gottschick C.

PEMBROLIZUMAB AND TRASTUZUMAB IN COMBINATION WITH FLOT IN THE PERIOPERATIVE TREATMENT OF HER2-POSITIVE, LOCALIZED ESOPHAGOGASTRIC ADENOCARCINOMA-A PHASE II TRIAL OF THE AIO STUDY GROUP (AIO STO 0321)

Tintelnot J, Stein A, Al-Batran SE, Ettrich T, Götze T, Grün B, Haag GM, Heuer V, Hofheinz RD, Homann N, Bröring TS, Cruz MS, Kurreck A, Lorenzen S, Moosmann N, Müller C, Schuler M, Siegler G, Binder M, Gökkurt E.

ASSOCIATION BETWEEN VIRUS VARIANTS, VACCINATION, PREVIOUS INFECTIONS, AND POST-COVID-19 RISK

Diexer S, Klee B, Gottschick C, Xu C, Broda A, Purschke O, Binder M, Frese T, Girndt M, Hoell JI, Moor I, Gekle M, Mikolajczyk R.

GUIDELINE CONCORDANCE OF TREATMENT AND OUTCOMES AMONG ADULT NON-HODGKIN LYMPHOMA PATIENTS IN SUB-SAHARAN AFRICA: A MULTINATIONAL, POPULATION-BASED COHORT

Mezger NCS, Hämmerl L, Griesel M, Seraphin TP, Joko-Fru YW, Feuchtner J, Zietsman A, Péko JF, Tadesse F, Buziba NG, Wabinga H, Nyanchama M, Chokunonga E, Kéita M, N'da G, Lorenzoni CF, Akele-Akpo MT, Mezger JM, Binder M, Liu B, Bauer M, Henke O, Jemal A, Kantelhardt EJ.

FIRST-LINE TREATMENT OF UNRESECTABLE OR METASTATIC HER2 POSITIVE ESOPHAGOGASTRIC ADENOCARCINOMA: LIQUID BIOMARKER ANALYSIS OF THE PHASE 2 INTEGA TRIAL

Paschold L, Stein A, Thiele B, Tintelnot J, Henkes SS, Coith C, Schultheiß C, Pantel K, Riethdorf S, Binder M.

MACHINE LEARNING ANALYSIS OF HUMORAL AND CELLULAR RESPONSES TO SARS-COV-2 INFECTION IN YOUNG ADULTS

Marcinkevics R, Silva PN, Hankele AK, Dörnte C, Kadelka S, Csik K, Godbersen S, Goga A, Hasenöhrl L, Hirschi P, Kabakci H, LaPierre MP, Mayrhofer J, Title AC, Shu X, Baiioud N, Bernal S, Dassisti L, Saenz-de-Juano MD, Schmidhauser M, Silvestrelli G, Ulbrich SZ, Ulbrich TJ, Wyss T, Stekhoven DJ, Al-Quaddoomi FS, Yu S, Binder M, Schultheiß C, Zindel C, Kolling C, Goldhahn J, Seighalani BK, Zjablovskaja P, Hardung F, Schuster M, Richter A, Huang YJ, Lauer G, Baurmann H, Low JS, Vaqueirinho D, Jovic S, Piccoli L, Ciesek S, Vogt JE, Sallusto F, Stoffel M, Ulbrich SE.

T CELL REPERTOIRE BREADTH IS ASSOCIATED WITH THE NUMBER OF ACUTE RESPIRATORY INFECTIONS IN THE LOEWENKIDS BIRTH COHORT

Paschold L, Gottschick C, Langer S, Klee B, Diexer S, Aksentijevich I, Schultheiß C, Purschke O, Riese P, Trittel S, Haase R, Dressler F, Eberl W, Hübner J, Strowig T, Guzman CA, Mikolajczyk R, Binder M.

SAM-COMPETITIVE EZH2-INHIBITORS INDUCE PLATINUM RESISTANCE BY EZH2-INDEPENDENT INDUCTION OF ABC-TRANSPORTERS

Groß E, Hilger RA, Schümann FL, Bauer M, Bouska A, Rohde C, Willscher E, Lützkendorf J, Müller LP, Edemir B, Mueller T, Herling M, Binder M, Wickenhauser C, Iqbal J, Posern G, Weber T.

AUTOANTIGEN-SELECTED B CELLS ARE BYSTANDERS IN SPONTANEOUS T CELL-DRIVEN EXPERIMENTAL AUTOIMMUNE HEPATITIS

Lübbering D, Preti M, Schlott L, Schultheiß C, Weidemann S, Lohse AW, Binder M, Carambia A, Herkel J.

ANXIETY, DEPRESSIVE SYMPTOMS, AND DISTRESS OVER THE COURSE OF THE WAR IN UKRAINE IN THREE FEDERAL STATES IN GERMANY

Massag J, Diexer S, Klee B, Costa D, Gottschick C, Broda A, Purschke O, Opel N, Binder M, Sedding D, Frese T, Girndt M, Hoell J, Moor I, Rosendahl J, Gekle M, Mikolajczyk R.

IMMUNE SIGNATURES IN VARIANT SYNDROMES OF PRIMARY BILIARY CHOLANGITIS AND AUTOIMMUNE HEPATITIS.

Schultheiß C, Steinmann S, Willscher E, Paschold L, Lohse AW, Binder M.

MENTAL HEALTH IN GERMANY IN THE FIRST WEEKS OF THE RUSSO-UKRAINIAN WAR.

​Gottschick C, Diexer S, Massag J, Klee B, Broda A, Purschke O, Binder M, Sedding D, Frese T, Girndt M, Hoell JI, Michl P, Gekle M, Mikolajczyk R.

CIRCULATING TUMOR DNA IN HEAD AND NECK SQUAMOUS CELL CARCINOMA

​Brandt A, Thiele B, Schultheiß C, Daetwyler E, Binder M.

POMALIDOMIDE COMBINATIONS ARE A SAFE AND EFFECTIVE OPTION AFTER DARATUMUMAB FAILURE.

Brioli A, Gengenbach L, Mancuso K, Binder M, Ernst T, Heidel FH, Stauch T, Zamagni E, Hilgendorf I, Hochhaus A, Engelhardt M, von Lilienfeld-Toal M.

NO ASSOCIATION OF MALIGNANT B-CELL NON-HODGKIN LYMPHOMAS WITH IPSILATERAL SARS-COV-2 VACCINATION.

Claaß LV, Mayr P, Paschold L, Weber T, Terziev D, Jehs B, Brill R, Dober J, Märkl B, Wickenhauser C, Czapiewski P, Trepel M, Claus R, Binder M.

REDUCED PROLIFERATION OF BONE MARROW MSC AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IS ASSOCIATED WITH CLINICAL OUTCOME.

Katzerke C, Schaffrath J, Lützkendorf J, Janssen M, Merbach AK, Nerger K, Binder M, Baum C, Lauer K, Rohde C, Willscher E, Müller-Tidow C, Mueller LP.

ACTIVATED GRANULOCYTES AND INFLAMMATORY CYTOKINE SIGNALING DRIVE T-CELL LYMPHOMA PROGRESSION AND DISEASE SYMPTOMS.

Jaeger A, Gambheer SMM, Sun X, Chernyakov D, Skorobohatko O, Mack TM, Kissel S, Pfeifer D, Zeiser R, Fisch P, Andrieux G, Bräuer-Hartmann D, Bauer M, Schulze S, Follo M, Boerries M, von Bubnoff N, Miething C, Hidalgo JV, Klein C, Weber T, Wickenhauser C, Binder M, Dierks C.

LIQUID BIOMARKERS OF MACROPHAGE DYSREGULATION AND CIRCULATING SPIKE PROTEIN ILLUSTRATE THE BIOLOGICAL HETEROGENEITY IN PATIENTS WITH POST-ACUTE SEQUELAE OF COVID-19.

Schultheiß C, Willscher E, Paschold L, Gottschick C, Klee B, Henkes SS, Bosurgi L, Dutzmann J, Sedding D, Frese T, Girndt M, Höll JI, Gekle M, Mikolajczyk R, Binder M.

2022

TRANSLATIONAL ANALYSIS AND FINAL EFFICACY OF THE AVETUX TRIAL – AVELUMAB, CETUXIMAB AND FOLFOX IN METASTATIC COLORECTAL CANCER.

Tintelnot J, Ristow I, Sauer M, Simnica D, Schultheiß C, Scholz R, Goekkurt E, von Wenserski L, Willscher E, Paschold L, Lorenzen S, Riera-Knorrenschild J, Depenbusch R, Ettrich T, Doerfel S, Al-Batran SE, Karthaus, M, Pelzer U, Waberer L, Hinke A, Bauer M, Massa C, Seliger B, Wickenhauser C, Bokemeyer C, Hegewisch-Becker S, Binder M, Stein A.

CHARACTERIZATION OF THE T CELL RECEPTOR REPERTOIRE AND MELANOMA TUMOR MICROENVIRONMENT UPON COMBINED TREATMENT WITH IPILIMUMAB AND HTERT VACCINATION

Ellingsen EB, Bounova G, Kerzeli I, Anzar I, Simnica D, Aamdal E, Guren T, Clancy T, Mezheyeuski A, Inderberg EM, Mangsbo SM, Binder M, Hovig E, Gaudernack G.

CURSE AND BLESSING: UPREGULATION OF ONCOGENES UPON TREATMENT WITH HYPOMETHYLATING AGENTS IN MYELODYSPLASTIC SYNDROME

Grimm J, Binder M.

PD-L1 AMINO ACID POSITION 88 REPRESENTS A HOTSPOT FOR PD-L1 STABILITY WITH RELEVANCE FOR PD-L1 INHIBITION

​Claaß LV, Schultheiß C, Scholz R, Paschold L, Simnica D, Heinemann V, Stintzing S, Binder M.

HOMOLOGOUS RECOMBINATION REPAIR DEFICIENT PROSTATE CANCER REPRESENTS AN IMMUNOLOGICALLY DISTINCT SUBTYPE

van Wilpe S, Simnica D, Slootbeek P, van Ee T, Pamidimarri Naga S, Gorris MAJ, van der Woude LL, Sultan S, Koornstra RHT, van Oort IM, Gerritsen WR, Kroeze LI, Simons M, van Leenders GJLH, Binder M, de Vries IJM, Mehra N.

EFFICACY OF IPILIMUMAB VS FOLFOX IN COMBINATION WITH NIVOLUMAB AND TRASTUZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ERBB2-POSITIVE ESOPHAGOGASTRIC ADENOCARCINOMA: THE AIO INTEGA RANDOMIZED CLINICAL TRIAL.

Stein A, Paschold L, Tintelnot J, Goekkurt E, Henkes SS, Simnica D, Schultheiss C, Willscher E, Bauer M, Wickenhauser C, Thuss-Patience P, Lorenzen S, Ettrich T, Riera-Knorrenschild J, Jacobasch L, Kretzschmar A, Kubicka S, Al-Batran SE, Reinacher-Schick A, Pink D, Sinn M, Lindig U, Hiegl W, Hinke A, Hegewisch-Becker S, Binder M.

​THE IL-1Β, IL-6, AND TNF CYTOKINE TRIAD IS ASSOCIATED WITH POST-ACUTE SEQUELAE OF COVID-19

Schultheiß C, Willscher E, Paschold L, Gottschick C, Klee B, Henkes SS, Bosurgi L, Dutzmann J, Sedding D, Frese T, Girndt M, Höll JI, Gekle M, Mikolajczyk R, Binder M.

B CELLS IN AUTOIMMUNE LIVER DISEASES: BYSTANDERS OR CENTRAL PLAYERS?

Schultheiß C, Steinmann S, Lohse AW, Binder M.

RAPID HYPERMUTATION B CELL TRAJECTORY RECRUITS PREVIOUSLY PRIMED B CELLS UPON THIRD SARS-COV-2 mRNA VACCINATION

Paschold L, Klee B, Gottschick C, Willscher E, Diexer S, Schultheiß C, Simnica D, Sedding D, Girndt M, Gekle M, Mikolajczyk R, Binder M.

SUBCLONAL HETEROGENEITY SHEDS LIGHT ON THE TRANSFORMATION TRAJECTORY IN IGLV3-21 R110 CHRONIC LYMPHOCYTIC LEUKEMIA

Paschold L, Simnica D, Brito RB, Zhang T, Schultheiß C, Dierks C, Binder M.

LONGITUDINAL HUMORAL AND CELLULAR IMMUNE RESPONSES FOLLOWING SARS-COV-2 VACCINATION IN PATIENTS WITH MYELOID AND LYMPHOID NEOPLASMS COMPARED TO A REFERENCE COHORT: RESULTS OF A PROSPECTIVE TRIAL OF THE EAST GERMAN STUDY GROUP FOR HEMATOLOGY AND ONCOLOGY (OSHO)

Jotschke S, Schulze S, Jaekel N, Ludwig-Kraus B, Engelmann R, Kraus FB, Zahn C, Nedlitz N, Prange-Krex G, Mohm J, Peuser B, Schwarz M, Spohn C, Behlendorf T, Binder M, Junghanss C, Böttcher S, Al-Ali HK.

OVERCOMING UNINTENDED IMMUNOGENICITY IN IMMUNOCOMPETENT MOUSE MODELS OF METASTASIS: THE CASE OF GFP

Schultheiß C, Binder M.

CIRCULATING TUMOR DNA IN GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER

Paschold L, Binder M.

2021

DIVERGENT EFFECTS OF EZH1 AND EZH2 PROTEIN EXPRESSION ON THE PROGNOSIS OF PATIENTS WITH T-CELL LYMPHOMAS

Schümann FL, Groß E, Bauer M, Rohde C, Sandmann S, Terziev D, Müller LP, Posern G, Wienke A, Fend F, Hansmann ML, Klapper W, Rosenwald A, Stein H, Dugas M, Müller-Tidow C, Wickenhauser C, Binder M, Weber T.

CORRELATION OF NUTRITION-ASSOCIATED PARAMETERS WITH NON-RELAPSE MORTALITY IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Schaffrath J, Diederichs T, Unverzagt S, Wass M, Gläser U, Weber T, Binder M, Müller-Tidow C, Müller LP.

THE IL-1ß, IL-6 AND TNF-Α CYTOKINE TRIAD IS ASSOCIATED WITH POST-ACUTE SEQUELAE OF COVID-19

Schultheiß C, Willscher E, Paschold L, Gottschick C, Klee B, Henkes SS, Bosurgi L, Dutzmann J, Sedding D, Frese T, Girndt M, Höll JI, Gekle M, Mikolajczyk R, Binder M.

MATURATION TRAJECTORIES AND TRANSCRIPTIONAL LANDSCAPE OF PLASMABLASTS AND AUTOREACTIVE B CELLS IN COVID-19

Schultheiß C, Paschold L, Willscher E, Simnica D, Wöstemeier A, Muscate F, Wass M, Eisenmann S, Dutzmann J, Keyßer G, Gagliani N, Binder M.

RBMX PROTEIN EXPRESSION IN T-CELL LYMPHOMAS PREDICTS CHEMOTHERAPY RESPONSE AND PROGNOSIS

Schümann FL, Bauer M, Groß E, Terziev D, Wienke A, Wickenhauser C, Binder M, Weber T.

LANDSCAPE OF T-CELL REPERTOIRES WITH PUBLIC COVID-19-ASSOCIATED T-CELL RECEPTORS IN PRE-PANDEMIC RISK COHORTS

Simnica D, Schultheiß C, Mohme M, Paschold L, Willscher E, Fitzek A, Püschel K, Matschke J, Ciesek S, Sedding DG, Zhao Y, Gagliani N, Maringer Y, Walz JS, Heide J, Schulze-Zur-Wiesch J, Binder M.

DETECTION OF SARS-COV-2 DERIVED SMALL RNAS AND CHANGES IN CIRCULATING SMALL RNAS ASSOCIATED WITH COVID-19

Grehl C, Schultheiß C, Hoffmann K, Binder M, Altmann T, Grosse I, Kuhlmann M.

THE AUTOIMMUNE SIGNATURE OF HYPERINFLAMMATORY MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN

Porritt RA, Binek A, Paschold L, Rivas MN, McArdle A, Yonker LM, Alter G, Chandnani HK, Lopez M, Fasano A, Van Eyk JE, Binder M, Arditi M.

PD-L1 TARGETING AND SUBCLONAL IMMUNE ESCAPE MEDIATED BY PD-L1 MUTATIONS IN METASTATIC COLORECTAL CANCER

Stein A, Simnica D, Schultheiß C, Scholz R, Tintelnot J, Gökkurt E, von Wenserski L, Willscher E, Paschold L, Sauer M, Lorenzen S, Riera-Knorrenschild J, Depenbusch R, Ettrich TJ, Dörfel S, Al-Batran SE, Karthaus M, Pelzer U, Waberer L, Hinke A, Bauer M, Massa C, Seliger B, Wickenhauser C, Bokemeyer C, Hegewisch-Becker S, Binder M.

OUTCOME OF A REAL-WORLD PATIENT COHORT WITH SECONDARY CNS LYMPHOMA TREATED WITH HIGH-INTENSITY CHEMOIMMUNOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION

Thiele B, Binder M, Schliffke S, Frenzel C, Dierlamm J, Wass M, Weisel KC, Bokemeyer C, Janjetovic S.

ANALYZING TYROSINE KINASE ACTIVITY IN HEAD AND NECK CANCER BY FUNCTIONAL KINOMICS: IDENTIFICATION OF HYPERACTIVATED SRC FAMILY KINASES AS PROGNOSTIC MARKERS AND POTENTIAL TARGETS

Bußmann L, Hoffer K, von Bargen CM, Droste C, Lange T, Kemmling J, Schröder-Schwarz J, Vu AT, Akingunsade L, Nollau P, Rangarajan S, de Wijn R, Oetting A, Müller C, Böckelmann LC, Zech HB, Berger JC, Möckelmann N, Busch CJ, Böttcher A, Gatzemeier F, Klinghammer K, Simnica D, Binder M, Struve N, Rieckmann T, Schumacher U, Clauditz TS, Betz CS, Petersen C, Rothkamm K, Münscher A, Kriegs M.

EVOLUTIONARY CLONAL TRAJECTORIES IN NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA WITH HIGH RISK OF TRANSFORMATION

Paschold L, Willscher E, Bein J, Vornanen M, Eichenauer DA, Simnica D, Thiele B, Wickenhauser C, Rosenwald A, Bernd HW, Klapper W, Feller AC, Ott G, Fend F, Hartmann S, Binder M.

HLA CLASS I-ASSOCIATED EXPANSION OF TRBV11-2 T CELLS IN MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN

Porritt RA, Paschold L, Rivas MN, Cheng MH, Yonker LM, Chandnani H, Lopez M, Simnica D, Schultheiß C, Santiskulvong C, Van Eyk J, McCormick JK, Fasano A, Bahar I, Binder M, Arditi M.

CLONAL EXPANSION AND ACTIVATION OF TISSUE-RESIDENT MEMORY-LIKE TH17 CELLS EXPRESSING GM-CSF IN THE LUNGS OF SEVERE COVID-19 PATIENTS

Zhao Y, Kilian C, Turner JE, Bosurgi L, Roedl K, Bartsch P, Gnirck AC, Cortesi F, Schultheiß C, Hellmig M, Enk LUB, Hausmann F, Borchers A, Wong MN, Paust HJ, Siracusa F, Scheibel N, Herrmann M, Rosati E, Bacher P, Kylies D, Jarczak D, Lütgehetmann M, Pfefferle S, Steurer S, Zur-Wiesch JS, Puelles VG, Sperhake JP, Addo MM, Lohse AW, Binder M, Huber S, Huber TB, Kluge S, Bonn S, Panzer U, Gagliani N, Krebs CF.

SARS-COV-2-SPECIFIC ANTIBODY REARRANGEMENTS IN PREPANDEMIC IMMUNE REPERTOIRES OF RISK COHORTS AND PATIENTS WITH COVID-19

Paschold L, Simnica D, Willscher E, Vehreschild MJ, Dutzmann J, Sedding DG, Schultheiß C, Binder M.

SLAMF RECEPTORS NEGATIVELY REGULATE B CELL RECEPTOR SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA VIA RECRUITMENT OF PROHIBITIN-2

von Wenserski L, Schultheiß C, Bolz S, Schliffke S, Simnica D, Willscher E, Gerull H, Wolters-Eisfeld G, Riecken K, Fehse B, Altfeld M, Nollau P, Binder M.

NEXT-GENERATION IMMUNOSEQUENCING REVEALS PATHOLOGICAL T-CELL ARCHITECTURE IN AUTOIMMUNE HEPATITIS

Schultheiß C, Simnica D, Willscher E, Oberle A, Fanchi L, Bonzanni N, Wildner NH, Schulze Zur Wiesch J, Weiler-Normann C, Lohse AW, Binder M.

A PROOF OF CONCEPT PHASE I/II PILOT TRIAL OF LSD1 INHIBITION BY TRANYLCYPROMINE COMBINED WITH ATRA IN REFRACTORY/RELAPSED AML PATIENTS NOT ELIGIBLE FOR INTENSIVE THERAPY

Wass M, Göllner S, Besenbeck B, Schlenk RF, Mundmann P, Göthert JR, Noppeney R, Schliemann C, Mikesch JH, Lenz G, Dugas M, Wermke M, Röllig C, Bornhäuser M, Serve H, Platzbecker U, Foerster KI, Burhenne J, Haefeli WE, Müller LP, Binder M, Pabst C, Müller-Tidow C; Study Alliance Leukemia (SAL).

2020

RESPONSIVENESS TO IMMUNE CHECKPOINT INHIBITORS IS ASSOCIATED WITH A PERIPHERAL BLOOD T-CELL SIGNATURE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Simnica D, Smits M, Willscher E, Fanchi LF, Kloots ISH, van Oort I, Gerritsen W, Mehra N, Binder M.

TARGETING THE MUTATIONAL LANDSCAPE OF BYSTANDER CELLS: DRUG-PROMOTED BLOOD CANCER FROM HIGH-PREVALENCE PRE-NEOPLASIAS IN PATIENTS ON BRAF INHIBITORS

Simnica D, Ittrich H, Bockemeyer C, Stein A, Binder M.

SUPERANTIGENIC CHARACTER OF AN INSERT UNIQUE TO SARS-COV-2 SPIKE SUPPORTED BY SKEWED TCR REPERTOIRE IN PATIENTS WITH HYPERINFLAMMATION

Cheng MH, Zhang S, Porritt RA, Noval Rivas M, Paschold L, Willscher E, Binder M, Arditi M, Bahar I.

PHASE III STUDY OF NIVOLUMAB ALONE OR COMBINED WITH IPILIMUMAB AS IMMUNOTHERAPY VERSUS STANDARD OF CARE IN RESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA

Zech HB, Moeckelmann N, Boettcher A, Muenscher A, Binder M, Vettorazzi E, Bokemeyer C, Schafhausen P, Betz CS, Busch CJ.

NEXT-GENERATION SEQUENCING OF T AND B CELL RECEPTOR REPERTOIRES FROM COVID-19 PATIENTS SHOWED SIGNATURES ASSOCIATED WITH SEVERITY OF DISEASE

Schultheiß C, Paschold L, Simnica D, Mohme M, Willscher E, von Wenserski L, Scholz R, Wieters I, Dahlke C, Tolosa E, Sedding DG, Ciesek S, Addo M, Binder M.

IMPACT OF BONE MARROW INVOLVEMENT ON OUTCOME IN RELAPSED AND REFRACTORY TRANSPLANT ELIGIBLE DIFFUSE LARGE B-CELL LYMPHOMA AND TRANSFORMED INDOLENT LYMPHOMA

Terziev D, Bauer M, Paschold L, Wickenhauser C, Wienke A, Binder M, Müller LP, Weber T.

IPILIMUMAB OR FOLFOX WITH NIVOLUMAB AND TRASTUZUMAB IN PREVIOUSLY UNTREATED HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC ESOPHAGOGASTRIC ADENOCARCINOMA - THE RANDOMIZED PHASE 2 INTEGA TRIAL (AIO STO 0217)

Tintelnot J, Goekkurt E, Binder M, Thuss-Patience P, Lorenzen S, Knorrenschild JR, Kretzschmar A, Ettrich T, Lindig U, Jacobasch L, Pink D, Al-Batran SE, Hinke A, Hegewisch-Becker S, Nilsson S, Bokemeyer C, Stein A.

NANOBODY-BASED CD38-SPECIFIC HEAVY CHAIN ANTIBODIES INDUCE KILLING OF MULTIPLE MYELOMA AND OTHER HEMATOLOGICAL MALIGNANCIES

Schriewer L, Schütze K, Petry K, Hambach J, Fumey W, Koenigsdorf J, Baum N, Menzel S, Rissiek B, Riecken K, Fehse B, Röckendorf JL, Schmid J, Albrecht B, Pinnschmidt H, Ayuk F, Kröger N, Binder M, Schuch G, Hansen T, Haag F, Adam G, Koch-Nolte F, Bannas P.

CLINICAL PRESENTATION AND DIAGNOSIS OF ADULT PATIENTS WITH NON-HODGKIN LYMPHOMA IN SUB-SAHARAN AFRICA

Mezger NCS, Feuchtner J, Griesel M, Hämmerl L, Seraphin TP, Zietsman A, Péko JF, Tadesse F, Buziba NG, Wabinga H, Nyanchama M, Borok MZ, Kéita M, N'da G, Lorenzoni CF, Akele-Akpo MT, Gottschick C, Binder M, Mezger J, Jemal A, Parkin DM, Wickenhauser C, Kantelhardt EJ.

CANCER CELLS EXPRESSING ONCOGENIC RAT SARCOMA SHOW DRUG-ADDICTION TOWARD EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES MEDIATED BY SUSTAINED MAPK SIGNALING

Tintelnot J, Metz S, Trentmann M, Oberle A, von Wenserski L, Schultheiß C, Braig F, Kriegs M, Fehse B, Riecken K, Bokemeyer C, Stein A, Binder M.

LOCAL INTRACEREBRAL IMMUNOMODULATION USING INTERLEUKIN-EXPRESSING MESENCHYMAL STEM CELLS IN GLIOBLASTOMA

Mohme M, Maire CL, Geumann U, Schliffke S, Dührsen L, Fita K, Akyüz N, Binder M, Westphal M, Guenther C, Lamszus K, Hermann FG, Schmidt NO.

CANCER CELLS EXPRESSING ONCOGENIC RAT SARCOMA SHOW DRUG-ADDICTION TOWARD EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES MEDIATED BY SUSTAINED MAPK SIGNALING

Tintelnot J, Metz S, Trentmann M, Oberle A, von Wenserski L, Schultheiß C, Braig F, Kriegs M, Fehse B, Riecken K, Bokemeyer C, Stein A, Binder M.

2019

T CELL RECEPTOR NEXT-GENERATION SEQUENCING REVEALS CANCER-ASSOCIATED REPERTOIRE METRICS AND RECONSTITUTION AFTER CHEMOTHERAPY IN PATIENTS WITH HEMATOLOGICAL AND SOLID TUMORS

Simnica D, Akyüz N, Schliffke S, Mohme M, V Wenserski L, Mährle T, Fanchi LF, Lamszus K, Binder M.

HIGH ALDEHYDE DEHYDROGENASE LEVELS ARE DETECTABLE IN THE SERUM OF PATIENTS WITH LUNG CANCER AND MAY BE EXPLOITED AS SCREENING BIOMARKERS

Rossi A, Voigtlaender M, Klose H, Schlüter H, Schön G, Loges S, Paolini M, Bokemeyer C, Reck M, Tarro G, Binder M.

HIGH-THROUGHPUT IMMUNOGENETICS REVEALS A LACK OF PHYSIOLOGICAL T CELL CLUSTERS IN PATIENTS WITH AUTOIMMUNE CYTOPENIAS

Simnica D, Schliffke S, Schultheiß C, Bonzanni N, Fanchi LF, Akyüz N, Gösch B, Casar C, Thiele B, Schlüter J, Lohse AW, Binder M.

MONOCLONAL GAMMOPATHY OF UNKNOWN SIGNIFICANCE - A COMMON INCIDENTAL FINDING - WHAT IS TO BE THOUGHT OF? WHAT HAS TO BE DONE?

Schieferdecker A, Binder M, Weisel K, Bokemeyer C.

THE BURDEN OF HEPATITIS E AMONG PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES: A RETROSPECTIVE EUROPEAN COHORT STUDY

von Felden J, Alric L, Pischke S, Aitken C, Schlabe S, Spengler U, Giordani MT, Schnitzler P, Bettinger D, Thimme R, Xhaard A, Binder M, Ayuk F, Lohse AW, Cornelissen JJ, de Man RA, Mallet V.

FULMINANT BLAST CRISIS WITH DE NOVO 11Q23 REARRANGEMENT IN A PHILADELPHIA-POSITIVE CML PATIENT UNDERGOING TREATMENT WITH DASATINIB

Janjetovic S, Asemissen AM, Dicker F, Binder M, Dierlamm J, Bokemeyer C, Schafhausen P.

T-CELL REPERTOIRE PROFILING BY NEXT-GENERATION SEQUENCING REVEALS TISSUE MIGRATION DYNAMICS OF TRBV13-FAMILY CLONOTYPES IN A COMMON EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS MOUSE MODEL

Schliffke S, Carambia A, Akyüz N, Thiele B, Herkel J, Binder M.

NANOBODY TARGETING OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ECTODOMAIN VARIANTS OVERCOMES RESISTANCE TO THERAPEUTIC EGFR ANTIBODIES

Tintelnot J, Baum N, Schultheiß C, Braig F, Trentmann M, Finter J, Fumey W, Bannas P, Fehse B, Riecken K, Schuetze K, Bokemeyer C, Rösner T, Valerius T, Peipp M, Koch-Nolte F, Binder M.

DIFFERENTIAL ORGANIZATION OF TONIC AND CHRONIC B CELL ANTIGEN RECEPTORS IN THE PLASMA MEMBRANE

Gomes de Castro MA, Wildhagen H, Sograte-Idrissi S, Hitzing C, Binder M, Trepel M, Engels N, Opazo F.

DEEP SEQUENCING OF BONE MARROW MICROENVIRONMENTS OF PATIENTS WITH DEL(5Q) MYELODYSPLASTIC SYNDROME REVEALS IMPRINTS OF ANTIGENIC SELECTION AS WELL AS GENERATION OF NOVEL T-CELL CLUSTERS AS A RESPONSE PATTERN TO LENALIDOMIDE

Mährle T, Akyüz N, Fuchs P, Bonzanni N, Simnica D, Germing U, Asemissen AM, Jann JC, Nolte F, Hofmann WK, Nowak D, Binder M.

A SIGNIFICANT PROPORTION OF PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA HARBOR CLONAL BONE MARROW B-CELLS

Brandt A, Matschke J, Fehrle W, von Wenserski L, Bokemeyer C, Illerhaus G, Binder M.

2018

EUROPEAN MYELOMA NETWORK RECOMMENDATIONS ON TOOLS FOR THE DIAGNOSIS AND MONITORING OF MULTIPLE MYELOMA: WHAT TO USE AND WHEN

Caers J, Garderet L, Kortüm KM, O'Dwyer ME, van de Donk NWCJ, Binder M, Dold SM, Gay F, Corre J, Beguin Y, Ludwig H, Larocca A, Driessen C, Dimopoulos MA, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Delforge M, Auner HW, Terpos E, Engelhardt M.

A SIGNIFICANT PROPORTION OF PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA HARBOR CLONAL BONE MARROW B-CELLS

Brandt A, Matschke J, Fehrle W, von Wenserski L, Bokemeyer C, Illerhaus G, Binder M.

DYNAMIC CHANGES OF THE NORMAL B LYMPHOCYTE REPERTOIRE IN CLL IN RESPONSE TO IBRUTINIB OR FCR CHEMO-IMMUNOTHERAPY

Schliffke S, Sivina M, Kim E, von Wenserski L, Thiele B, Akyüz N, Falker-Gieske C, Statovci D, Oberle A, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger JA, Binder M.

THE PHOSPHOTYROSINE PHOSPHATASE SHP2 PROMOTES ANERGY IN CHRONIC LYMPHOCYTIC LEUKEMIA

Schliffke S, Buhs S, Bolz S, Gerull H, von Wenserski L, Riecken K, Fehse B, Nollau P, Binder M.

IMMUNOPHENOTYPING OF NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA DEFINES DISTINCT IMMUNE EXHAUSTION PROFILES IN PERIPHERAL AND TUMOR-INFILTRATING LYMPHOCYTES

Mohme M, Schliffke S, Maire CL, Rünger A, Glau L, Mende KC, Matschke J, Gehbauer C, Akyüz N, Zapf S, Holz M, Schaper M, Martens T, Schmidt NO, Peine S, Westphal M, Binder M, Tolosa E, Lamszus K.

2017

NANOBODIES EFFECTIVELY MODULATE THE ENZYMATIC ACTIVITY OF CD38 AND ALLOW SPECIFIC IMAGING OF CD38 + TUMORS IN MOUSE MODELS IN VIVO

Fumey W, Koenigsdorf J, Kunick V, Menzel S, Schütze K, Unger M, Schriewer L, Haag F, Adam G, Oberle A, Binder M, Fliegert R, Guse A, Zhao YJ, Cheung Lee H, Malavasi F, Goldbaum F, van Hegelsom R, Stortelers C, Bannas P, Koch-Nolte F.

WHOLE-BRAIN RADIOTHERAPY OR AUTOLOGOUS STEM-CELL TRANSPLANTATION AS CONSOLIDATION STRATEGIES AFTER HIGH-DOSE METHOTREXATE-BASED CHEMOIMMUNOTHERAPY IN PATIENTS WITH PRIMARY CNS LYMPHOMA: RESULTS OF THE SECOND RANDOMISATION OF THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP-32 PHASE 2 TRIAL

Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG).

THE ROLE OF B CELL ANTIGEN RECEPTORS IN MANTLE CELL LYMPHOMA

Fichtner M, Dreyling M, Binder M, Trepel M.

LONG-TERM CD38 SATURATION BY DARATUMUMAB INTERFERES WITH DIAGNOSTIC MYELOMA CELL DETECTION

Oberle A, Brandt A, Alawi M, Langebrake C, Janjetovic S, Wolschke C, Schütze K, Bannas P, Kröger N, Koch-Nolte F, Bokemeyer C, Binder M.

MONITORING MULTIPLE MYELOMA BY NEXT-GENERATION SEQUENCING OF V(D)J REARRANGEMENTS FROM CIRCULATING MYELOMA CELLS AND CELL-FREE MYELOMA DNA

Oberle A, Brandt A, Voigtlaender M, Thiele B, Radloff J, Schulenkorf A, Alawi M, Akyüz N, März M, Ford CT, Krohn-Grimberghe A, Binder M.

CETUXIMAB RESISTANCE IN HEAD AND NECK CANCER IS MEDIATED BY EGFR-K 521 POLYMORPHISM

Braig F, Kriegs M, Voigtlaender M, Habel B, Grob T, Biskup K, Blanchard V, Sack M, Thalhammer A, Ben Batalla I, Braren I, Laban S, Danielczyk A, Goletz S, Jakubowicz E, Märkl B, Trepel M, Knecht R, Riecken K, Fehse B, Loges S, Bokemeyer C, Binder M.

T-CELL DIVERSIFICATION REFLECTS ANTIGEN SELECTION IN THE BLOOD OF PATIENTS ON IMMUNE CHECKPOINT INHIBITION AND MAY BE EXPLOITED AS LIQUID BIOPSY BIOMARKER

Akyüz N, Brandt A, Stein A, Schliffke S, Mährle T, Quidde J, Goekkurt E, Loges S, Haalck T, Ford CT, Asemissen AM, Thiele B, Radloff J, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Binder M.

RESISTANCE TO ANTI-CD19/CD3 BITE IN ACUTE LYMPHOBLASTIC LEUKEMIA MAY BE MEDIATED BY DISRUPTED CD19 MEMBRANE TRAFFICKING

Braig F, Brandt A, Goebeler M, Tony HP, Kurze AK, Nollau P, Bumm T, Böttcher S, Bargou RC, Binder M.

2016

MODIFYING THERAPY IN PATIENTS WITH ADVANCED HODGKIN'S LYMPHOMA BY INTEGRATING EARLY METABOLIC RESPONSE BY INTERIM PET-CT

Bacher U, Binder M.

COMPLEMENTARITY DETERMINING REGION-INDEPENDENT RECOGNITION OF A SUPERANTIGEN BY B-CELL ANTIGEN RECEPTORS OF MANTLE CELL LYMPHOMA

Fichtner M, Spies E, Seismann H, Riecken K, Engels N, Gösch B, Dierlamm J, Gerull H, Nollau P, Klapper W, Dreyling M, Binder M, Trepel M.

DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE FOR MULTIPLE MYELOMA

Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators.

HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HAEMOPOIETIC STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA: A PROSPECTIVE, SINGLE-ARM, PHASE 2 TRIAL

Illerhaus G, Kasenda B, Ihorst G, Egerer G, Lamprecht M, Keller U, Wolf HH, Hirt C, Stilgenbauer S, Binder M, Hau P, Edinger M, Frickhofen N, Bentz M, Möhle R, Röth A, Pfreundschuh M, von Baumgarten L, Deckert M, Hader C, Fricker H, Valk E, Schorb E, Fritsch K, Finke J.

RADIOSENSITIZATION OF HNSCC CELLS BY EGFR INHIBITION DEPENDS ON THE INDUCTION OF CELL CYCLE ARRESTS

Kriegs M, Kasten-Pisula U, Riepen B, Hoffer K, Struve N, Myllynen L, Braig F, Binder M, Rieckmann T, Grénman R, Petersen C, Dikomey E, Rothkamm K.

CHEMOIMMUNOTHERAPY WITH METHOTREXATE, CYTARABINE, THIOTEPA, AND RITUXIMAB (MATRIX REGIMEN) IN PATIENTS WITH PRIMARY CNS LYMPHOMA: RESULTS OF THE FIRST RANDOMISATION OF THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP-32 (IELSG32) PHASE 2 TRIAL

Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG).

LIQUID BIOPSY MONITORING UNCOVERS ACQUIRED RAS-MEDIATED RESISTANCE TO CETUXIMAB IN A SUBSTANTIAL PROPORTION OF PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA

Braig F, Voigtlaender M, Schieferdecker A, Busch CJ, Laban S, Grob T, Kriegs M, Knecht R, Bokemeyer C, Binder M.

A TRANSPLANT "IMMUNOME" SCREENING PLATFORM DEFINES A TARGETABLE EPITOPE FINGERPRINT OF MULTIPLE MYELOMA

Schieferdecker A, Oberle A, Thiele B, Hofmann F, Göthel M, Miethe S, Hust M, Braig F, Voigt M, von Pein UM, Koch-Nolte F, Haag F, Alawi M, Indenbirken D, Grundhoff A, Bokemeyer C, Bacher U, Kröger N, Binder M.

OSTEOLYTIC LESIONS OCCUR RARELY IN PATIENTS WITH B-CLL AND MAY RESPOND WELL TO IBRUTINIB

Shumilov E, Wulf G, Ströbel P, Hasenkamp J, Hellige N, Bleckmann A, Haase D, Braulke F, Jung W, Schanz J, Binder M, Trümper L, Bacher U.

BENDAMUSTINE AND RITUXIMAB IN COMBINATION WITH LENALIDOMIDE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

Maurer C, Pflug N, Bahlo J, Kluth S, Rhein C, Cramer P, Gross-Ophoff C, Langerbeins P, Fink AM, Eichhorst B, Kreuzer KA, Fischer N, Tausch E, Stilgenbauer S, Böttcher S, Döhner H, Kneba M, Dreyling M, Binder M, Hallek M, Wendtner CM, Bergmann M, Fischer K; German CLL Study Group.

SEVERE AND IRREVERSIBLE MYELOPATHY AFTER CONCURRENT SYSTEMIC AND INTRATHECAL NUCLEOSIDE ANALOGUE TREATMENT FOR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A CASE REPORT AND REVIEW OF THE LITERATURE

Alsdorf WH, Schmitz M, Schieferdecker A, Dierlamm J, Bokemeyer C, Binder M.

2015

COMMENT ON "PRIMARY CENTRAL NERVOUS SYSTEM (CNS) LYMPHOMA B CELL RECEPTORS RECOGNIZE CNS PROTEINS"

Spies E, Fichtner M, Müller F, Krasemann S, Illerhaus G, Glatzel M, Binder M, Trepel M.

EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION MEDIATES CROSS-RESISTANCE TO PANITUMUMAB AND CETUXIMAB IN GASTROINTESTINAL CANCER

Braig F, März M, Schieferdecker A, Schulte A, Voigt M, Stein A, Grob T, Alawi M, Indenbirken D, Kriegs M, Engel E, Vanhoefer U, Grundhoff A, Loges S, Riecken K, Fehse B, Bokemeyer C, Binder M.

HOSPITAL POPULATION SCREENING REVEALS OVERREPRESENTATION OF CD5(-) MONOCLONAL B-CELL LYMPHOCYTOSIS AND MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OF IGM TYPE

Voigtlaender M, Vogler B, Trepel M, Panse J, Jung R, Bokemeyer C, Bacher U, Binder M.

CD229 IS EXPRESSED ON THE SURFACE OF PLASMA CELLS CARRYING AN ABERRANT PHENOTYPE AND CHEMOTHERAPY-RESISTANT PRECURSOR CELLS IN MULTIPLE MYELOMA

Yousef S, Kovacsovics-Bankowski M, Salama ME, Bhardwaj N, Steinbach M, Langemo A, Kovacsovics T, Marvin J, Binder M, Panse J, Kröger N, Luetkens T, Atanackovic D.

THE ROLE OF T-CELL PHENOTYPE AND T-CELL RECEPTOR REARRANGEMENT IN THE DIAGNOSIS OF T-CELL MALIGNANCIES: AUTHOR'S REPLY

Flammiger A, Binder M.

SEVERE AND IRREVERSIBLE MYELOPATHY AFTER CONCURRENT SYSTEMIC AND INTRATHECAL NUCLEOSIDE ANALOGUE TREATMENT FOR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A CASE REPORT AND REVIEW OF THE LITERATURE

Alsdorf WH, Schmitz M, Schieferdecker A, Dierlamm J, Bokemeyer C, Binder M.

MULTIPARAMETER FLOW CYTOMETRY IN THE DIFFERENTIAL DIAGNOSIS OF ABERRANT T-CELL CLONES OF UNCLEAR SIGNIFICANCE

Flammiger A, Bacher U, Christopeit M, Horn C, Rühlmann E, Kluge K, Vettorazzi E, Bokemeyer C, Binder M.

2014

DENOSUMAB MIMICS THE NATURAL DECOY RECEPTOR OSTEOPROTEGERIN BY INTERACTING WITH ITS MAJOR BINDING SITE ON RANKL

Schieferdecker A, Voigt M, Riecken K, Braig F, Schinke T, Loges S, Bokemeyer C, Fehse B, Binder M.

NEXT-GENERATION SEQUENCING OF PERIPHERAL B-LINEAGE CELLS PINPOINTS THE CIRCULATING CLONOTYPIC CELL POOL IN MULTIPLE MYELOMA

Thiele B, Kloster M, Alawi M, Indenbirken D, Trepel M, Grundhoff A, Binder M.

MULTIDIMENSIONAL SCALING ANALYSIS IDENTIFIES PATHOLOGICAL AND PROGNOSTICALLY RELEVANT PROFILES OF CIRCULATING T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA

Rissiek A, Schulze C, Bacher U, Schieferdecker A, Thiele B, Jacholkowski A, Flammiger A, Horn C, Haag F, Tiegs G, Zirlik K, Trepel M, Tolosa E, Binder M.

THE ROLE OF CD81 FOR PLASMA CELL DYSCRASIAS

Binder M, Bacher U.

2013

AXL, A PROGNOSTIC AND THERAPEUTIC TARGET IN ACUTE MYELOID LEUKEMIA MEDIATES PARACRINE CROSSTALK OF LEUKEMIA CELLS WITH BONE MARROW STROMA

Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas-Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens JB, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S.

CLL B-CELL RECEPTORS CAN RECOGNIZE THEMSELVES: ALTERNATIVE EPITOPES AND STRUCTURAL CLUES FOR AUTOSTIMULATORY MECHANISMS IN CLL

Binder M, Müller F, Frick M, Wehr C, Simon F, Leistler B, Veelken H, Mertelsmann R, Trepel M.

OUTCOME OF ALLOGENEIC SCT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN THE ERA OF TYROSINE KINASE INHIBITOR THERAPY

Oyekunle A, Zander AR, Binder M, Ayuk F, Zabelina T, Christopeit M, Stübig T, Alchalby H, Schafhausen P, Lellek H, Wolschke C, Müller I, Bacher U, Kröger N.

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN OPTION FOR LONG-TERM SURVIVAL FOR PATIENTS WITH SIMULTANEOUS APPEARANCE OF MYELOID AND LYMPHATIC MALIGNANCIES

Weber T, Ocheni S, Binder M, Theurich S, Scheid C, Schmid C, Müller LP, Christopeit M, Bacher U.

2012

FUNCTIONAL DISSECTION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR EPITOPES TARGETED BY PANITUMUMAB AND CETUXIMAB

Voigt M, Braig F, Göthel M, Schulte A, Lamszus K, Bokemeyer C, Binder M.

ACCELERATION OF COLLATERAL DEVELOPMENT BY CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE 1 EXPRESSION ON CD11B/⁺GR-1⁺ MYELOID CELLS--BRIEF REPORT

Bickert T, Marshall RP, Zhang Z, Ludewig P, Binder M, Klinke A, Rottbauer W, Amling M, Wagener C, Ito WD, Horst AK.

CRITICAL IMBALANCE OF TNF-Α AND SOLUBLE TNF RECEPTOR 1 IN A PATIENT WITH MACROPHAGE ACTIVATION SYNDROME: POTENTIAL IMPLICATIONS FOR DIAGNOSTICS AND TREATMENT

Flammiger A, Fiedler W, Bacher U, Bokemeyer C, Schneider M, Binder M.

PHENOTYPIC DETECTION OF CLONOTYPIC B CELLS IN MULTIPLE MYELOMA BY SPECIFIC IMMUNOGLOBULIN LIGANDS REVEALS THEIR RARITY IN MULTIPLE MYELOMA

Trepel M, Martens V, Doll C, Rahlff J, Gösch B, Loges S, Binder M.

ANTIGEN-SPECIFICITY OF OLIGOCLONAL ABNORMAL PROTEIN BANDS IN MULTIPLE MYELOMA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

Rahlff J, Trusch M, Haag F, Bacher U, Horst A, Schlüter H, Binder M.

ANTI-TUMOR ACTIVITY OF A B-CELL RECEPTOR-TARGETED PEPTIDE IN A NOVEL DISSEMINATED LYMPHOMA XENOGRAFT MODEL

Wehr C, Müller F, Schüler J, Tomann T, Nitschke C, Seismann H, Spillner E, Klingner K, Schneider-Merck T, Binder M, Fiebig HH, Mertelsmann R, Trepel M.

IDENTIFICATION OF GENETIC PARAMETERS ASSOCIATED WITH DISEASE PROGRESSION IN PLASMA CELL MYELOMA

Bacher U, Binder M.

2011

ANTI-TUMOR ACTIVITY OF A B-CELL RECEPTOR-TARGETED PEPTIDE IN A NOVEL DISSEMINATED LYMPHOMA XENOGRAFT MODEL

Wehr C, Müller F, Schüler J, Tomann T, Nitschke C, Seismann H, Spillner E, Klingner K, Schneider-Merck T, Binder M, Fiebig HH, Mertelsmann R, Trepel M.

IDENTIFICATION OF GENETIC PARAMETERS ASSOCIATED WITH DISEASE PROGRESSION IN PLASMA CELL MYELOMA

Bacher U, Binder M.

B-CELL RECEPTOR EPITOPE RECOGNITION CORRELATES WITH THE CLINICAL COURSE OF CHRONIC LYMPHOCYTIC LEUKEMIA

Binder M, Müller F, Jackst A, Léchenne B, Pantic M, Bacher U, Zu Eulenburg C, Veelken H, Mertelsmann R, Pasqualini R, Arap W, Trepel M.

2010

STEREOTYPICAL CHRONIC LYMPHOCYTIC LEUKEMIA B-CELL RECEPTORS RECOGNIZE SURVIVAL PROMOTING ANTIGENS ON STROMAL CELLS

Binder M, Léchenne B, Ummanni R, Scharf C, Balabanov S, Trusch M, Schlüter H, Braren I, Spillner E, Trepel M.

2008

XXIII INTERNATIONAL ASSOCIATION FOR COMPARATIVE RESEARCH ON LEUKEMIA AND RELATED DISEASES SYMPOSIUM: FROM MOLECULAR PATHOGENESIS TO TARGETED THERAPY IN LEUKEMIA AND SOLID TUMORS

Hackanson B, Becker H, Berg T, Binder M, Dierks C, Duque-Afonso J, Lairmore MD, Schäfer HS, Schnitzler M, Zeiser R, Martens U, Mertelsmann R, Lübbert M.

2006

THE EPITOPE RECOGNIZED BY RITUXIMAB

Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M.

bottom of page